CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Payments to Acquire Marketable Securities
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Payments to Acquire Marketable Securities of $42.13 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2017-11-09
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for the quarter ending 2017-09-30 was $12.16M, a 461.10% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for the quarter ending 2017-07-01 was $23.28M, a 98.69% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for the quarter ending 2017-04-01 was $6.70M, a 4.74% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for the quarter ending 2016-12-31 was $19.97M, a 152.15% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for fiscal 2016 was $40.25M, a 17.56% increase from fiscal 2015.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for fiscal 2015 was $34.23M, a 28.47% increase from fiscal 2014.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for fiscal 2014 was $26.65M, a 51.70% increase from fiscal 2013.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. payments to acquire marketable securities for fiscal 2013 was $17.57M, a 5.24% decline from fiscal 2012.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2017-09-30 | $12.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $35.44M derived: sum of 2 quarters · filed 2017-11-09 | $42.13M 10-Q · filed 2017-11-09 | $62.10M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-07-01 | $23.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $29.98M 10-Q · filed 2017-08-09 | $49.95M derived: sum of 3 quarters · filed 2017-08-09 | $52.11M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-04-01 | $6.70M 10-Q · filed 2017-05-10 | $26.67M derived: sum of 2 quarters · filed 2017-05-10 | $28.84M derived: sum of 3 quarters · filed 2017-11-09 | $40.55M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-12-31 | $19.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $22.14M derived: sum of 2 quarters · filed 2017-11-09 | $33.85M derived: sum of 3 quarters · filed 2017-11-09 | $40.25M 10-K · filed 2017-02-14 |
| 2016-09-24 | $2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $13.88M derived: sum of 2 quarters · filed 2017-11-09 | $20.28M 10-Q · filed 2017-11-09 | $28.20M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-25 | $11.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $18.11M 10-Q · filed 2017-08-09 | $26.03M derived: sum of 3 quarters · filed 2017-08-09 | $37.17M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-26 | $6.39M 10-Q · filed 2017-05-10 | $14.31M derived: sum of 2 quarters · filed 2017-05-10 | $25.46M derived: sum of 3 quarters · filed 2017-05-10 | $30.91M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-26 | $7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $19.06M derived: sum of 2 quarters · filed 2017-02-14 | $24.51M derived: sum of 3 quarters · filed 2017-02-14 | $34.23M 10-K · filed 2017-02-14 |
| 2015-09-26 | $11.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $16.59M derived: sum of 2 quarters · filed 2016-11-02 | $26.32M 10-Q · filed 2016-11-02 | $34.79M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-27 | $5.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $15.17M 10-Q · filed 2016-08-03 | $23.65M derived: sum of 3 quarters · filed 2017-02-14 | $32.09M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-28 | $9.72M 10-Q · filed 2016-05-04 | $18.20M derived: sum of 2 quarters · filed 2017-02-14 | $26.64M derived: sum of 3 quarters · filed 2017-02-14 | $29.67M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-27 | $8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $16.91M derived: sum of 2 quarters · filed 2017-02-14 | $19.94M derived: sum of 3 quarters · filed 2017-02-14 | $26.65M 10-K · filed 2017-02-14 |
| 2014-09-27 | $8.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $11.47M derived: sum of 2 quarters · filed 2015-11-04 | $18.17M 10-Q · filed 2015-11-04 | $20.40M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-28 | $3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $9.73M 10-Q · filed 2015-07-30 | $11.96M derived: sum of 3 quarters · filed 2016-02-12 | $20.89M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-29 | $6.71M 10-Q · filed 2015-04-30 | $8.93M derived: sum of 2 quarters · filed 2016-02-12 | $17.86M derived: sum of 3 quarters · filed 2016-02-12 | $20.42M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-28 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $11.15M derived: sum of 2 quarters · filed 2016-02-12 | $13.72M derived: sum of 3 quarters · filed 2016-02-12 | $17.57M 10-K · filed 2016-02-12 |
| 2013-09-28 | $8.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $11.49M derived: sum of 2 quarters · filed 2014-10-30 | $15.34M 10-Q · filed 2014-10-30 | $23.06M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-29 | $2.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $6.41M 10-Q · filed 2014-08-07 | $14.14M derived: sum of 3 quarters · filed 2015-02-17 | $16.77M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-30 | $3.85M 10-Q · filed 2014-04-30 | $11.57M derived: sum of 2 quarters · filed 2015-02-17 | $14.21M derived: sum of 3 quarters · filed 2015-02-17 | $17.69M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-29 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $10.36M derived: sum of 2 quarters · filed 2015-02-17 | $13.84M derived: sum of 3 quarters · filed 2015-02-17 | $18.54M 10-K · filed 2015-02-17 |
| 2012-09-29 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $6.12M derived: sum of 2 quarters · filed 2013-10-30 | $10.81M 10-Q · filed 2013-10-30 | $15.53M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $3.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $8.18M 10-Q · filed 2013-07-31 | $12.90M derived: sum of 3 quarters · filed 2014-02-25 | $17.40M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $4.69M 10-Q · filed 2013-05-08 | $9.41M derived: sum of 2 quarters · filed 2014-02-25 | $13.92M derived: sum of 3 quarters · filed 2014-02-25 | $19.70M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $9.22M derived: sum of 2 quarters · filed 2014-02-25 | $15.01M derived: sum of 3 quarters · filed 2014-02-25 | $24.56M 10-K · filed 2014-02-25 |
| 2011-09-24 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $10.29M derived: sum of 2 quarters · filed 2012-11-01 | $19.84M 10-Q · filed 2012-11-01 | $20.83M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-25 | $5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $15.33M 10-Q · filed 2012-08-07 | $16.33M derived: sum of 3 quarters · filed 2013-02-27 | $25.43M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-26 | $9.55M 10-Q · filed 2012-05-04 | $10.54M derived: sum of 2 quarters · filed 2013-02-27 | $19.64M derived: sum of 3 quarters · filed 2013-02-27 | $30.42M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-25 | $997.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $10.10M derived: sum of 2 quarters · filed 2013-02-27 | $20.88M derived: sum of 3 quarters · filed 2013-02-27 | $27.60M 10-K · filed 2013-02-27 |
| 2010-09-25 | $9.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $19.88M derived: sum of 2 quarters · filed 2011-11-02 | $26.60M 10-Q · filed 2011-11-02 | $71.64M derived: sum of 4 quarters · filed 2012-02-27 |
| 2010-06-26 | $10.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $17.50M 10-Q · filed 2011-08-03 | $62.54M derived: sum of 3 quarters · filed 2012-02-27 | $62.16M derived: sum of 4 quarters · filed 2012-02-27 |
| 2010-03-27 | $6.72M 10-Q · filed 2011-05-04 | $51.76M derived: sum of 2 quarters · filed 2012-02-27 | $51.38M derived: sum of 3 quarters · filed 2012-02-27 | |
| 2009-12-26 | $45.03M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $44.66M derived: sum of 2 quarters · filed 2012-02-27 | $98.99M 10-K · filed 2012-02-27 | |
| 2009-09-26 | -$374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $53.96M 10-Q · filed 2010-11-04 | ||
| 2009-06-27 | $54.33M 10-Q · filed 2010-08-03 | |||
| 2008-12-27 | $6.44M 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |